<DOC>
	<DOCNO>NCT01043263</DOCNO>
	<brief_summary>The purpose study determine efficacy safety EN3324 ( axomadol ) subject moderate severe chronic low back pain</brief_summary>
	<brief_title>Efficacy Safety EN3324 ( Axomadol ) Subjects With Chronic Low Back Pain</brief_title>
	<detailed_description>A phase IIB , randomize , double-blind , two-arm , multi-center , placebo-controlled , study assess efficacy safety EN3324 ( axomadol ) subject moderate severe chronic low back pain</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>18 year age old Are females participate abstinence use medically acceptable form contraception postmenopausal , biologically sterile , surgically sterile 1 year . Have unchanged regimen analgesic medication chronic low back pain daily basis least 3 month prior screen ; subject take opioids must exceed total daily dose 90mg oral morphine equivalent Have history moderate severe CLBP Have evidence history alcohol and/or drug abuse Have pain secondary confirm suspected neoplasm Intend alter physical therapy regimen study . Subjects begin end physical therapy ( either home exercise formal therapy session ) 2 week prior screen study period exclude study Have history physical examination finding , may confound painrelated data ( e.g. , fibromyalgia , radiculopathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>